Latest Ipsen News & Updates

See the latest news and media coverage for Ipsen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Ipsen

Global specialty biopharmaceutical company

ipsen.com

Headquarters: Paris, France
Company type: Public company
Number of employees: 6,700–10,000
Industry: Pharmaceuticals

Last updated October 22

Latest news about Ipsen

In short: Ipsen reported strong 2026 sales growth, upgraded guidance, and completed two acquisitions while advancing its pipeline.

Company announcements

October 22 Ipsen

Ipsen upgrades financial guidance after strong sales growth

Total sales grew 24.6% year-to-date. The company acquired Memo and Kartos Therapeutics to strengthen its pipeline.

August 21 Ipsen

Ipsen completes acquisition of Kartos Therapeutics

This strengthens the late-stage Oncology pipeline with navtemadlin for myelofibrosis treatment.

July 30 Ipsen

Ipsen delivers excellent H1 2026 results and upgrades guidance

Sales grew 23.5% at CER, core operating margin reached 38.6%, and full-year guidance was raised.

July 24 Ipsen

Ipsen announces BOLD trial missed primary endpoint

The Phase III trial for biliary atresia did not improve native liver survival versus placebo.

Media coverage

October 22 GuruFocus

Q3 2026 Ipsen SA Corporate Sales Call Transcript

Oct 22, 2026 / 11:00AM GMTOperator Hello, and welcome to Ipsen's conference call and webcast on Q3 2026 results. I'll now hand you over to...

October 21 Les Echos

Ipsen raises its 2026 targets again after nine-month revenue better than expected

PARIS (Agefi-Dow Jones)--Pharmaceutical laboratory Ipsen raised its 2026 targets for the second time this year on Thursday, as its nine-month revenue...

September 20 The Wall Street Journal

Ipsen Shares Fall After Early Launch of U.S. Generic Rival

Stock fell sharply after the U.S. Food and Drug Administration approved a generic competitor to its...

September 15 Idéal Investisseur

Ipsen drops 7% after US green light for a generic version of Somatuline

Ipsen shares fell more than 7% on Monday morning on the Paris Stock Exchange following authorization in the United States for a generic version of lanreotide, the...

Never miss news about Ipsen

Track Ipsen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Ipsen competitors & trending companies

Browse news for competitors to Ipsen and other trending companies.